Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2449 - Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Motoyuki Suzuki

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

M. Suzuki1, N. Takemoto1, T. Fukuzumi1, M. Yamamoto1, S. Otozai2, T. Yoshii2, T. Fujii2, H. Inohara1

Author affiliations

  • 1 Otorhinolaryngology-head And Neck Surgery, Osaka University Graduate School of Medicine, 565-0871 - Osaka/JP
  • 2 Head And Neck Surgery, Osaka International Cancer Institute, 541-8567 - Osaka/JP
More

Resources

Abstract 2449

Background

The standard first-line treatment for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is platinum-based chemotherapy, while the predictor of survival has yet to be established, except for tumor human papillomavirus (HPV) status. The present study aimed to evaluate the usefulness of metabolic tumor volume (MTV) measured on FDG-PET/CT in predicting survival of patients with R/M HNSCC after platinum-based chemotherapy.

Methods

Patients with R/M HNSCC treated with platinum-based chemotherapy as first-line treatment following FDG-PET/CT between 2006 and 2017 at Osaka University Medical School Hospital and Osaka International Cancer Institute were eligible. Exclusion criteria were nasopharyngeal carcinoma, >60 days duration between FDG-PET/CT and chemotherapy initiation. FDG-PET/CT data were transferred into the workstation in the DICOM format. A total amount of MTV in the whole body was measured using a SUV-based automated contouring program (PETSTAT Viewer Ver. 2.2), with the SUV threshold being 2.5. Tumor HPV status was determined by p16 immunohistochemistry. The risk of death was assessed by Cox proportional hazard model.

Results

One hundred and four patients met the criteria. The median follow-up duration of surviving patients was 13.1 months (range, 3.2-79.6). The median MTV was 21.9ml (range, 0.0-1118.7). The risk of death increased by 1.03 fold (95% confidence interval, 1.02-1.04; P < 0.0001) for every 10-ml increment of MTV, independently of tumor HPV status. The median overall survival was 15.3 months in patients with MTV larger than the median and 9.2 months in patients with MTV equal to or smaller than the median.

Conclusions

MTV is a useful predictor of survival in patients with R/M HNSCC after platinum-based chemotherapy. MTV needs to be considered in allocation for randomized clinical trials.

Clinical trial identification

Legal entity responsible for the study

M. Suzuki.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.